nterventional News has reported that the UK CAVA trial, a four way randomised controlled trial of long term venous access devices for the delivery of chemotherapy has begun.
The CAVA (Cancer and venous access) trial seeks to determine which device offers the best outcome from safety, clinical effectiveness and cost-effectiveness perspectives. The trial will randomise 2000 patients over three years and will be the world's largest venous access trial.
There is currently no evidence-based guidance to help choose between these devices and the decision making processes behind choice of device, which varies from centre to centre, is poorly understood.
To read the full article click here
or read more information about interventional oncology